A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I
Exploration · 2026-10 · 6 (5)
DOI: 10.1002/exp2.70226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration, online erschienen am 06.10.2026. Verfasst von Chuyu Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School…. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is characterized by low expression of major histocompatibility complex class I (MHC‐I), which significantly limits the efficacy of immunotherapy. In this work, bioinformatic analysis finds that elevated PCSK9 in HCC correlates with reduced T cell activity and poor prognosis. Based on these discoveries, a PD‐L1 nanobody‐engineered synthetic RNA virus (αPDL1‐VLPs/shPCSK9) is fabricated to inhibit PCSK9, thereby restoring MHC‐I expression to enhance HCC immunotherapy. The αPDL1‐VLPs/shPCSK9 is produced using MS2 virus‐like particles (VLPs) in Escherichia coli ( E. coli ), displaying PD‐L1 nanobodies and encapsulating PCSK9‐downregulating shRNA. Notably, αPDL1‐VLPs/shPCSK9 upregulates MHC‐I to enhance cytotoxic T lymphocytes (CTLs) recognition of tumor cells while promoting M2‐to‐M1 macrophages polarization, thereby boosting immunotherapy. In vivo studies indicate that αPDL1‐VLPs/shPCSK9 exhibits HCC tumor‐targeting behavior, suppressing primary tumor growth while avoiding systemic toxicity. Immunological analysis confirms that αPDL1‐VLPs/shPCSK9 enhances CTLs activation and infiltration, triggering systemic antitumor immunity to eradicate distant tumors. Overall, these findings highlight αPDL1‐VLPs/shPCSK9 as a promising therapeutic strategy for reversing the multiple immunosuppressive characteristics of HCC, providing a streamlined yet comprehensive approach to potentiate immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou Chi…
- GMU-GIBH Joint School of Life Sciences Guangzhou Medical University Guangzhou China.
- Department of Pathology, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Huang, C., Ye, Y., Guo, Y., Liao, G., Luo, L., Ding, L., Miao, Y., Zhao, L., Ouyang, Y., & Li, S. (2026). A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I. Exploration, 6(5). https://doi.org/10.1002/exp2.70226
Vancouver
Huang C, Ye Y, Guo Y, Liao G, Luo L, Ding L, et al. A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I. Exploration. 2026;6(5). doi:10.1002/exp2.70226
BibTeX
@article{Huang2026,
author = {Huang, Chuyu and Ye, Yun and Guo, Yi and Liao, Guozheng and Luo, Linyi and Ding, Lingwen and Miao, Yingling and Zhao, Linping and Ouyang, Yongchang and Li, Shiying},
title = {A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I},
journal = {Exploration},
year = {2026},
volume = {6},
number = {5},
doi = {10.1002/exp2.70226}
}
EUVIMED